Efficacy evaluation of percutaneous osteoplasty combined with 131I therapy and survival analysis in patients with bone metastasis from differentiated thyroid carcinoma
10.3760/cma.j.cn321828-20200302-00082
- VernacularTitle:经皮骨水泥成形术联合 131I治疗分化型甲状腺癌骨转移的疗效评价与生存分析
- Author:
Jianwen SUN
1
;
Hongjun SONG
;
Chuang XI
;
Chungen WU
;
Chentian SHEN
;
Zhongling QIU
;
Quanyong LUO
Author Information
1. 上海交通大学附属第六人民医院核医学科，上海 200233
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2020;40(6):339-342
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy of percutaneous osteoplasty (POP) combined with 131I therapy in patients with bone metastases from differentiated thyroid carcinoma (DTC) and assess the survival. Methods:From Januray 2008 to January 2020, 29 DTC patients with bone metastases (16 males, 13 females, age range: 24-64 years) who received POP combined with 131I therapy in Shanghai Sixth People′s Hospital were retrospectively analyzed. Clinical data and characteristics of patients were analyzed. The efficacy and prognosis were evaluated based on the changes of serum thyroglobulin (Tg) and relieving condition of bone pain after the combined treatment. χ2 test was used to determine the association between clinical characteristics and efficacy, and Kaplan-Meier analysis was used to estimate the overall survival (OS) rate. Results:The biochemical response rate of serum Tg was 68.97% (20/29) after the combined treatment. For the influence on changes of serum Tg, whether or not combined with non-osseous distant metastasis, and cumulative dose of 131I treatment(≥22.2 vs <22.2 GBq) were statistically significant ( χ2 values: 5.448 and 4.371, both P<0.05). The rate of bone pain relief was 65.52%(19/29). Age (≥55 vs <55 years) and the cumulative dose of 131I treatment had statistically influences on bone relief ( χ2 values: 7.486 and 5.154, both P<0.05). The 5-years OS rate of patients was 87.68%, while the 10-years OS rate was 65.76%. Conclusion:POP combined with 131I therapy is effective on relieving the pain, reducing the serum Tg to some extent, and improving the long-term survival of DTC patients with bone metastasis.
